Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation

Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment